¡Ya estamos en ! Descubre más

Simulations Plus

SLP

Excluida de cotización

SLP dejó de cotizar en bolsa el 5 de octubre de 2026.

Volver al ranking

Acerca de: Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.

Empleados: 213

Atención médica Servicios de información de salud

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 0%

Neutral 100%

Negativo 0%

Simulations Plus Announces Funded Partnership with Global Pharmaceutical Company to Advance AI-Enabled QSP Model Development with Turin

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a funded partnership with a global large pharmaceutical company to apply Turin, its AI-enabled scientific engine for quantitative systems pharmacology (QSP), within an active therapeutic development program. The collaboration will evaluate how AI-enabled.

Simulations Plus Announces Funded Partnership with Global Pharmaceutical Company to Advance AI-Enabled QSP Model Development with Turin

Simulations Plus Announces Completion of Acquisition by Altaris

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the completion of its acquisition by affiliates of Altaris, LLC ("Altaris"), an investment firm focused exclusively on the healthcare industry.The transaction was originally announced on June 16, 2026. At the effective time of the merger each Simulations.

Simulations Plus Announces Completion of Acquisition by Altaris

Simulations Plus Expands FDA Adoption of ADMET Predictor® with New Licenses for the Cosmetics Regulatory Science Branch

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that the U.S. Food and Drug Administration's (FDA) Cosmetics Regulatory Science Branch has licensed ADMET Predictor® to support its computational research for modern cosmetic safety assessment. The contract expands the use of Simulations Plus technology.

Simulations Plus Expands FDA Adoption of ADMET Predictor® with New Licenses for the Cosmetics Regulatory Science Branch

Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

San Diego, California--(Newsfile Corp. - September 15, 2026) - Johnson Fistel, PLLP is investigating Simulations Plus, Inc. (NASDAQ: SLP) for investors who suffered losses and whether they may recover those losses under federal securities laws. Click here to join the investigation.

Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

SAN DIEGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating Simulations Plus, Inc. (NASDAQ: SLP) for investors who suffered losses and whether they may recover those losses under federal securities laws.

Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating Simulations Plus, Inc. (NASDAQ: SLP) for investors who suffered losses and whether they may recover those losses under federal securities laws.

Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

SAN DIEGO, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating Simulations Plus, Inc. (NASDAQ: SLP) for investors who suffered losses and whether they may recover those losses under federal securities laws. On April 3, 2025, Simulations Plus reported its financial results for the second quarter of fiscal 2025 and maintained full-year revenue guidance of $90 million to $93 million.

Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

Simulations Plus Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by Altaris

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the Company's previously announced acquisition by Altaris, LLC. The expiration of the HSR waiting period satisfies one of the regulatory cond.

Simulations Plus Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by Altaris

Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating Simulations Plus, Inc. (NASDAQ: SLP) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws.

Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

Simulations Plus Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Simulations Plus, Inc. - SLP

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Simulations Plus, Inc. (NasdaqGS: SLP) to affiliates of Altaris, LLC. Under the terms of the proposed transaction, shareholders of Simulations will receive $18.50 in cash for each share of Simulations that they own. KSF is seeking to determine whether this consideration and the process that led to i.

Simulations Plus Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Simulations Plus, Inc. - SLP

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™